Coty Inc header image

Coty Inc

COTY

Equity

ISIN null / Valor 1645885

New York Stock Exchange, Inc (2025-11-18)
USD 3.31-1.19%

Coty Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Coty Inc. is a global beauty company with a history that spans over a century, marking its significance in transforming the beauty industry into what it is today. The company boasts a diverse portfolio of over 50 iconic cosmetic, skincare, and fragrance brands. Coty's business strategy is rooted in innovation and excellence, aiming to empower and enable all visions of beauty through its products. The company emphasizes the importance of science and passion as key drivers behind its mission to offer new, innovative, and science-based beauty solutions. Coty Inc. positions itself as a forward-thinking entity in the beauty sector, dedicated to supporting diverse and evolving concepts of beauty that resonate with individuals on a personal level.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (18.11.2025):

Coty Inc. reported its Q1 FY26 financial results, ending September 30, 2025, with overall performance in line with expectations and Q2 sales tracking toward the more favorable end of prior guidance. Despite a 6% year‐over‐year decline in reported net revenue to $1,577.2 million, the Company noted encouraging trends in its U.S. Prestige fragrance segment and continued to drive strategic initiatives aimed at a return to profitable sales and growth in the second half of FY26.

Financial Performance

Coty Inc.'s Q1 FY26 results showed reported net revenue of $1,577.2 million, down 6% YoY (8% on a like-for-like basis). Reported operating income declined to $185.0 million while adjusted operating income fell by 21% to $240.5 million. Both reported and adjusted EPS saw comparable declines, with reported EPS at $0.07 and adjusted EPS at $0.12.

Margin and EBITDA Trends

The Company experienced a 100 basis point decline in gross margins, now at 64.5%. Adjusted EBITDA reached $296.1 million, marking an 18% decrease, with the adjusted EBITDA margin down by 270 basis points to 18.8%.

Strategic Initiatives and Market Position

Coty Inc. is focused on reinforcing its global leadership in fragrance and scenting through innovation and strategic integration. Key initiatives include the accelerated roll-out of innovative launches like BOSS Bottled Beyond and expansions into scenting adjacencies, a review of its mass cosmetics and Brazil businesses, and more closely integrating its Prestige Beauty and Mass Fragrance segments.

Market and Operational Highlights

The U.S. Prestige fragrance sell-out grew by a mid-to-high single digit percentage in Q1, aligning it with overall market trends. Additionally, the Company noted strong retail performance in China, robust e-commerce gains, and advancements in cost discipline and agility, setting the stage for improved results in Q2 and a return to growth in the second half of FY26.

Balance Sheet and Financial Health

At quarter-end, Coty Inc. reported total debt of $4,069.3 million and financial net debt of $3,804.7 million, with a debt to net income ratio of 11.1x and a net debt to adjusted EBITDA ratio of 3.7x. The Company’s 25.8% stake in Wella was valued at $1,003.0 million, underscoring its robust asset positioning amid ongoing strategic investments.

Summarized from source with an LLMView Source

Key figures

-53.2%1Y
-57.4%3Y
-37.5%5Y

Performance

51.2%1Y
41.2%3Y
49.3%5Y

Volatility

Market cap

2887 M

Market cap (USD)

Daily traded volume (Shares)

6,741,955

Daily traded volume (Shares)

1 day high/low

6.99 / 6.81

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Getinge AB
Getinge AB Getinge AB Valor: 84926
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%SEK 207.10
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.96%USD 65.59
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC Valor: 14769757
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
6.13%USD 180.52
Viking Therapeutics Inc
Viking Therapeutics Inc Viking Therapeutics Inc Valor: 24839858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.20%USD 37.76
Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc Intra-Cellular Therapies Inc Valor: 23194616
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 131.87
Denali Therapeutics Inc
Denali Therapeutics Inc Denali Therapeutics Inc Valor: 39149539
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.63%USD 17.48
AstraZeneca PLC
AstraZeneca PLC AstraZeneca PLC Valor: 982352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.19%GBP 135.66
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.20%GBP 15.58
Spire Healthcare Group PLC
Spire Healthcare Group PLC Spire Healthcare Group PLC Valor: 24881418
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.55%GBP 2.23
National Healthcare Corp
National Healthcare Corp National Healthcare Corp Valor: 836282
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.75%USD 124.93